Senesco Signs Supply Agreement for Polyplus-transfection’s Delivery System
Complete the form below to unlock access to ALL audio articles.
Senesco Technologies, Inc. has announced that it has contracted with Polyplus-transfection to supply Polyplus’s “in vivo-jetPEI” for systemic delivery of Senesco’s combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid delivered with “in vivo-jetPEI” against subcutaneous multiple myeloma tumors in immunodeficient mice.
“This supply agreement will help Senesco move toward the necessary preclinical toxicology study and ultimately the planned clinical trial targeting multiple myeloma,” commented Bruce Galton, Senesco’s President and CEO. “Polyplus’ PEI technology is already being used in clinical oncology trials by other companies and we look forward to working with them and using their technology to deliver our Factor 5A technology.”
“We are proud that Senesco has chosen our delivery system targeting multiple myeloma and that we have an agreement to supply the company according to this agreement” said Joelle Bloch, CEO of Polyplus-transfection. “We are delighted that our “in vivo-jetPEI” will be used as delivery vehicle for a combination of siRNA and plasmid DNA in this therapeutic approach.”
